Nov 09, 2023 / 04:00PM GMT
Colin Nigel Bristow - UBS Investment Bank, Research Division - Analyst
Well, good morning, and welcome to the UBS BioPharma Conference. I'm Colin Bristow, one of the biotech analysts here. It's my pleasure to have Regeneron Pharmaceuticals with us today. On behalf of the company, we have Brook Jennings, VP of Commercial Dermatology; and Ryan Crowe, Head of Investor Relations. Thank you both for being with us today. I'll turn it over to you guys now. I know you have some sort of prepared remarks, and so I'll leave it to you. Thank you.
Ryan Crowe - Regeneron Pharmaceuticals, Inc. - VP of IR
Yes, we won't spend too much time on this, but let me first get the FLS disclosure out of the way. I'd like to remind you that our remarks made today may include forward-looking statements about Regeneron. Each forward-looking statement is subject to risks and uncertainty that could cause actual results and events to differ materially from those projected in such statements.
A description of material risks and uncertainties can be found in Regeneron's SEC filings.
Regeneron Pharmaceuticals Inc at UBS BioPharma Conference Transcript
Nov 09, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers